{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:23:44Z","timestamp":1781130224469,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bacterial infections such as osteomyelitis and endocarditis routinely require several weeks of treatment with intravenous (IV) antimicrobials. Outpatient parenteral antimicrobial therapy (OPAT) programs allow patients to receive IV antimicrobials in an outpatient clinic or at home. The outcomes and costs of such treatments remain uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective observational cohort study over a 5-year study interval (1 June 2012 to 31 March 2018) using population-based linked administrative data from British Columbia, Canada. Patients receiving OPAT following a hospitalization for bacterial infection were matched based on infection type and implied duration of IV antimicrobials to patients receiving inpatient parenteral antimicrobial therapy (IPAT). Cumulative adverse events and direct healthcare costs were estimated over a 90-day outcome interval.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In a matched cohort of 1842 patients, adverse events occurred in 35.6% of OPAT patients and 39.0% of IPAT patients (adjusted odds ratio, 1.04 [95% confidence interval {CI}, .83\u20131.30; P = .61). Relative to IPAT patients, OPAT patients were significantly more likely to experience hospital readmission (30.5% vs 23.0%) but significantly less likely to experience Clostridioides difficile diarrhea (1.2% vs 3.1%) or death (2.0% vs 8.8%). Estimated mean direct healthcare costs were $30 166 for OPAT patients and $50 038 for IPAT patients (cost ratio, 0.60; average cost savings with OPAT, $17 579 [95% CI, $14 131\u2013$21 027]; P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Outpatient IV antimicrobial therapy is associated with a similar overall prevalence of adverse events and with substantial cost savings relative to patients remaining in hospital to complete IV antimicrobials. These findings should inform efforts to expand OPAT use.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac298","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T04:00:04Z","timestamp":1649995204000},"page":"1921-1929","source":"Crossref","is-referenced-by-count":36,"title":["Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs"],"prefix":"10.1093","volume":"75","author":[{"given":"John A","family":"Staples","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Clinical Epidemiology & Evaluation , Vancouver , Canada"},{"name":"Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Health Evaluation & Outcome Sciences , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight","family":"Ferris","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hayek","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Health Evaluation & Outcome Sciences , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Health Evaluation & Outcome Sciences , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"2022113017002552100_ciac298-B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(14)60890-4","article-title":"Challenges of infectious diseases in the USA","volume":"384","author":"Khabbaz","year":"2014","journal-title":"Lancet"},{"key":"2022113017002552100_ciac298-B2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2022113017002552100_ciac298-B3","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2022113017002552100_ciac298-B4","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1086\/653520","article-title":"Outpatient parenteral antimicrobial therapy today","volume":"51","author":"Paladino","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022113017002552100_ciac298-B5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0891-5520(05)70022-2","article-title":"Evolution of outpatient parenteral antibiotic therapy","volume":"12","author":"Poretz","year":"1998","journal-title":"Infect Dis Clin North Am"},{"key":"2022113017002552100_ciac298-B6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1742-1241.2008.01824.x","article-title":"Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry","volume":"62","author":"Martone","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2022113017002552100_ciac298-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1472-6963-5-43","article-title":"Willingness to pay to assess patient preferences for therapy in a Canadian setting","volume":"5","author":"Marra","year":"2005","journal-title":"BMC Health Serv Res"},{"key":"2022113017002552100_ciac298-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022113017002552100_ciac298-B9","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dky133","article-title":"Emergency department visits during outpatient parenteral antimicrobial therapy: a retrospective cohort study","volume":"73","author":"Shrestha","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2017.03.016","article-title":"Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service","volume":"51","author":"Durojaiye","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2022113017002552100_ciac298-B11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijantimicag.2012.01.016","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years","volume":"39","author":"Barr","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2022113017002552100_ciac298-B12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00129804-200211000-00005","article-title":"The changing face of Canadian home parenteral therapy","volume":"25","author":"Goodwin","year":"2002","journal-title":"J Infus Nurs"},{"key":"2022113017002552100_ciac298-B13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijantimicag.2004.06.004","article-title":"Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison","volume":"24","author":"Esposito","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2022113017002552100_ciac298-B14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkm210","article-title":"Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years","volume":"60","author":"Matthews","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B15","doi-asserted-by":"crossref","first-page":"e013560","DOI":"10.1136\/bmjopen-2016-013560","article-title":"Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review","volume":"7","author":"Mitchell","year":"2017","journal-title":"BMJ Open"},{"key":"2022113017002552100_ciac298-B16","doi-asserted-by":"crossref","first-page":"14090","DOI":"10.1038\/npjpcrm.2014.90","article-title":"A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis","volume":"24","author":"Bedi","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"2022113017002552100_ciac298-B17","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/ciz030","article-title":"GAMES investigators. Outpatient parenteral antibiotic treatment (OPAT) for infective endocarditis: a prospective cohort study from the GAMES cohort","volume":"69","author":"Peric\u00e0s","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022113017002552100_ciac298-B18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9343(94)90283-6","article-title":"Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drug delivery device. HIAT study group","volume":"97","author":"Mauceri","year":"1994","journal-title":"Am J Med"},{"key":"2022113017002552100_ciac298-B19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9343(94)90286-0","article-title":"Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: global analysis of a large-scale, multicenter trial. HIAT study group","volume":"97","author":"Poretz","year":"1994","journal-title":"Am J Med"},{"key":"2022113017002552100_ciac298-B20","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/jac\/dkp051","article-title":"Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy","volume":"63","author":"Rehm","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw193","article-title":"Value and clinical impact of an infectious disease-supervised outpatient parenteral antibiotic therapy program","volume":"3","author":"Petrak","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2022113017002552100_ciac298-B22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14737167.2017.1360767","article-title":"Economic evaluation of outpatient parenteral antimicrobial therapy: a systematic review","volume":"17","author":"Psaltikidis","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2022113017002552100_ciac298-B23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2018.07.013","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) in the UK: a cross-sectional survey of acute hospital trusts and health boards","volume":"93","author":"Durojaiye","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022113017002552100_ciac298-B24","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s11606-021-06803-8","article-title":"Physician financial incentives to reduce unplanned hospital readmissions: an interrupted time series analysis","volume":"36","author":"Staples","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2022113017002552100_ciac298-B25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.healthpol.2012.02.007","article-title":"Bundles: an opportunity to align incentives for continuing care in Canada?","volume":"107","author":"Sutherland","year":"2012","journal-title":"Health Policy"},{"key":"2022113017002552100_ciac298-B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/bmj.38309.447975.EB","article-title":"Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital","volume":"330","author":"Corwin","year":"2005","journal-title":"BMJ"},{"key":"2022113017002552100_ciac298-B27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/8755122513500922","article-title":"The impact of an infectious diseases transition service on the care of outpatients on parenteral antimicrobial therapy","volume":"29","author":"Keller","year":"2013","journal-title":"J Pharm Technol"},{"key":"2022113017002552100_ciac298-B28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/IJGM.S230054","article-title":"Out of hospital and in hospital management of cellulitis requiring intravenous therapy","volume":"12","author":"Ong","year":"2019","journal-title":"Int J Gen Med"},{"key":"2022113017002552100_ciac298-B29","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1093\/jac\/dkv130","article-title":"Comparative outcomes of \u03b2-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches","volume":"70","author":"Lee","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022113017002552100_ciac298-B31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/cid\/cit211","article-title":"Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence","volume":"57","author":"Muldoon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022113017002552100_ciac298-B32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1542\/hpeds.2015-0069","article-title":"Adverse events in pediatric patients receiving long-term oral and intravenous antibiotics","volume":"6","author":"Murphy","year":"2016","journal-title":"Hosp Pediatr"},{"key":"2022113017002552100_ciac298-B33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/0897190016688771","article-title":"Characterization of drug-related problems occurring in patients receiving outpatient antimicrobial therapy","volume":"30","author":"Hale","year":"2017","journal-title":"J Pharm Pract"},{"key":"2022113017002552100_ciac298-B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijantimicag.2013.09.006","article-title":"Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade","volume":"43","author":"MacKenzie","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2022113017002552100_ciac298-B35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/jac\/dkv413","article-title":"False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia","volume":"71","author":"Kameshwar","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200018050-00004","article-title":"Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective","volume":"18","author":"Wai","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"2022113017002552100_ciac298-B37","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.clinthera.2015.09.009","article-title":"Outcomes and pharmacoeconomic analysis of a home intravenous antibiotic infusion program in veterans","volume":"37","author":"Ruh","year":"2015","journal-title":"Clin Ther"},{"key":"2022113017002552100_ciac298-B38","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/jac\/dkq355","article-title":"Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service","volume":"65","author":"Ho","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2022113017002552100_ciac298-B39","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/jac\/dkx203","article-title":"Successful outpatient parenteral antibiotic therapy delivery via telemedicine","volume":"72","author":"Tan","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac298\/43991971\/ciac298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/11\/1921\/47466326\/ciac298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/11\/1921\/47466326\/ciac298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T17:29:19Z","timestamp":1669829359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/11\/1921\/6570781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,4,19]]},"published-print":{"date-parts":[[2022,11,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac298","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,4,19]]}}}